Ilya Rachman

Chief Executive Officer presso IMMIX BIOPHARMA, INC.

Patrimonio netto: 3 M $ in data 31/03/2024

52 anni

Consumer Services

Health Technology

Profilo

Ilya Rachman is a Chairman & Chief Executive Officer and founder of Immix Biopharma, Inc. which is founded in 2012.
He is also currently an Executive Chairman at Nexcella, Inc. Dr. Rachman has an MBA from the University of California, Los Angeles, a graduate and doctorate degree from the University of Illinois, and an undergraduate degree from the University of Iowa.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
IMMIX BIOPHARMA, INC. 3.53%	14/08/2023	902 500 ( 3.53% )	3 M $	31/03/2024

Posizioni attive di Ilya Rachman

Società	Posizione	Inizio
IMMIX BIOPHARMA, INC.	Chief Executive Officer	01/01/2012
Nexcella, Inc. Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned.	Chairman	-

Tutte le posizioni attive di Ilya Rachman

Formazione di Ilya Rachman

University of California, Los Angeles	Masters Business Admin
University of Illinois	Doctorate Degree
University of Iowa	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Ilya Rachman

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
IMMIX BIOPHARMA, INC.	Health Technology

Aziende private	1
Nexcella, Inc. Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned.	Health Technology